Similarly, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, demonstrates a dose-dependent gradient of efficacy, with increasing weight reduction observed from 5 to 15 mg weekly [6]
Dose escalations: Each time the dose increases, GI symptoms may briefly return
Data extraction Information on the baseline characteristics of the samples enrolled included age, gender, proportion of patients with T2D, baseline BMI, TBWL%, waist circumference, body composition, proportion of patients achieving at least 5%, 10%, 15%, 20%, and 25% body weight reduction, remission or improvement/resolution of obesity-related complications, SAE, mortality, MACE, FPG, HbA1c, lipid profile, estimated glomerular filtration rate (eGFR), creatinine, albuminuria, mental health parameters and QoL
I came across a recent article discussing Degrader-Antibody Conjugates (DACs) and their potential to transform drug discovery, especially for previously undruggable targets
GLP-1 (glucagon-like peptide-1) is a hormone the body naturally produces after eating
In the meantime, a holistic approach is going to be the best way to optimize your bone health, rather than relying solely on pharmaceutical drugs.To get my full take on GLP-1 drugs and bone health, head to the link in my story!#DrDougLucas #OptimalHumanHealth #bonehealth #bonebuilding #glp1s | Dr